Posts about:
Case Studies
TCC Case Study: Sir Oliver
Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor.
Mammary Carcinoma Case Study: Missy
After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.
Squamous Cell Carcinoma Case Study: Duchess
It is clear that the utilization of targeted therapy has proven beneficial in improving patient quality of life, extending survival time with minimal disease progression, and having an overall positive impact on patient care.
Lung Carcinoma Case Study: Adley Hurwitz
After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence.
Hemophagocytic Histiocytic Sarcoma Case Study: Forrest
A 11 yr old Golden with hemophagocytic histiocytic sarcoma, 38 months in remission. FidoCure® identified a rare tumor suppressor mutation and suggested additional therapy that may have helped target tumor cells.
Thyroid Carcinoma Case Study: Lulu
After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary metastasis. Lulu has maintained a positive quality of life while in treatment and achieved extended time with her pet owners.
Splenic Hemangiosarcoma Case Study: Sam
After FidoCure® enabled treatment, Sam exceeded the 5-7 month median survival time for splenic hemangiosarcoma by living over one year beyond diagnosis.
Mesothelioma Case Study: Heidi
With combination therapy that included targeted therapy guided by FidoCure® genomic sequencing, Heidi has survived over a year following her initial diagnosis of mesothelioma and is still going strong.
